• 1
    Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—A Position Paper of the Obesity Society and the American Society of Hypertension. Obesity 2012. doi:10.1038/oby.20181.
  • 2
    Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007; 120( 10): 863-870.
  • 3
    Wassertheil-Smoller S, Fann C, Allman RM, et al. Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. The SHEP Cooperative Research Group. Arch Intern Med 2000; 160( 4): 494-500.
  • 4
    Lavie CJ, Milani RV, Ventura HO. Obesity, heart disease, and favorable prognosis--truth or paradox? Am J Med 2007; 120( 10): 825-826.
  • 5
    Stephen von H, Doehner W, Anker SD. Revisitng the obesity paradox in heart failure: new insights. Eur J Heart Fail 2011. doi:10.1093/eurjh/
  • 6
    Wing RR, Lang W, Wadden TA, et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabet Care 2011; 34: 1481-1486.
  • 7
    Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
  • 8
    Whelton PK, Barzilay J, Cushman WC, et al.; ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165( 12): 1401-1409.
  • 9
    Wright JT, Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168: 207-217.
  • 10
    Weber MA, Jamerson K, Bakris GL, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2012. doi: 10.1016/S0140–6736(12)61343–9.